drug · intermediate · partly written
Nirmatrelvir (given with ritonavir)
An oral SARS-CoV-2 main-protease inhibitor whose optimisation traded some enzyme potency for absorption.
Also called: PF-07321332, Paxlovid component
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
The lesson for lead optimisation
A cell-assay number belongs to the compound and the cell. The precursor looked far weaker in monkey cells than its enzyme potency suggested, in large part because the cells pump it out; the dose target was set from human-cell potency instead. Absorption, not enzyme potency, was what the oral series had to fix. 12
Reported, not yet replicated
What is not documented more
The edit-by-edit table from the oral series (a nitrile in place of the hydroxymethylketone, a trifluoroacetamide cap, a bicyclic proline) and the claim that nirmatrelvir had a weaker enzyme Ki but far better oral bioavailability come from a preprint that returned an access error at source check. They are not stated as findings here. The cause of the poor oral absorption is not apportioned among polarity, gut efflux, solubility and instability by any paper opened. Nearly all efflux evidence is from the maker's own authors; a non-maker replication exists for nirmatrelvir only. 12
Unverified: from our own report, source not opened
Modality
a record that is not published here
Targets
Indications
Mechanism
It blocks the virus's main protease, the enzyme that cuts the long viral protein into working pieces using a catalytic cysteine. It descends from an intravenous series (PF-00835231) whose warhead forms a reversible covalent bond to that cysteine. The two are different molecules and only the earlier one is described in the sources opened here. 21
Reported, not yet replicated
Delivery route
Must survive
Gut absorption and liver clearance. The intravenous parent was poorly absorbed by mouth (oral bioavailability under 2% in rat and monkey), and nirmatrelvir is cleared by CYP3A4, which is why it is given with ritonavir, a CYP3A4 blocker with no activity against the virus. The ritonavir arrangement leaves drug-interaction liability (the label was not opened). 13
Reported, not yet replicated
Assays used
Enzyme inhibition constant
PF-00835231 had a Ki of 0.27 nM against the SARS-CoV-2 protease. 1
Reported, not yet replicated
Cell antiviral EC50 with and without an efflux-pump inhibitor
In monkey Vero cells PF-00835231 read 39.7 and 88.9 uM in two lines and 0.23 and 0.76 uM when the pump P-glycoprotein was blocked; in human lung and fibroblast-derived cells the block made no statistically significant difference. A VeroE6 knockout of the pump gene gave a nirmatrelvir EC50 of 35 nM without inhibitor, against 45 nM in parent cells with inhibitor. 14
See: Dose-response assay, Potent on the enzyme, weak in cells: the compound or the cell?
Reported, not yet replicated
Gut-permeability assay could not rank the series
The ketone-based compounds showed very low permeability and high efflux, beyond the sensitivity of the Caco-2 assay, so the standard permeability test could not rank them. 2
See: Caco-2 permeability assay
Reported, not yet replicated
Off targets
Nearest off-target of the parent compound: cathepsin B
Two papers on PF-00835231 give different cathepsin B figures (an IC50 of 1.3 uM in one; 6.9 nM against 6 uM described as 1,000-fold weaker in the other, not labelled as IC50). Probably different runs; unresolved. Selectivity was inherited from the protease site, not fought for. 21
Contested
Verdict
Outcome
worked
Why
In the final EPIC-HR analysis (1,379 unvaccinated high-risk adults treated within 3 days of symptoms) hospitalisation or death to day 28 fell by 5.81 percentage points (95% CI -7.78 to -3.84), a relative risk reduction of 88.9%, with all deaths in the placebo group. The trial was supported by the maker. Patients' day-5 troughs ran about 5.4 times the dose target Pfizer had derived from a human-cell EC90, but only one dose was tested, so the trial cannot show where the true floor lies. 53
Reported, not yet replicated
Still open here
- Year and regulatory status are not written: the label and approval documents were not opened.
- The oral edit sequence needs the final Science paper or the preprint opened at source.
- The intravenous prodrug route and its later fate are not sourced here.
Not yet written: Pathways, Year, Regulatory status, Side effects.
Linked from
Sources
- Boras, Britton, Jones, Rhys M., Anson, Brandon J., et al.. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nature Communications (2021). paper; opened 2026-11-17 all records citing this
- Hoffman, Robert L., Kania, Robert S., Brothers, Mary A., et al.. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. Journal of Medicinal Chemistry (2020). paper; opened 2026-11-17 all records citing this
- Gerhart, Jacqueline, Cox, Donna S., Singh, Ravi Shankar P., et al.. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir. Clinical Pharmacokinetics (2024). paper; opened 2026-11-17 all records citing this
- Zhu, Yuao, Binder, Joe, Yurgelonis, Irina, et al.. Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study. Antiviral Research (2022). paper; opened 2026-11-17 all records citing this
- Hammond, Jennifer, Leister-Tebbe, Heidi, Gardner, Annie, et al.. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New England Journal of Medicine (2022). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/drugs/nirmatrelvir.json